Robert Langreth

Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials.

Cancer causing chemicals are found in yet more products.

UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.

Alkermes Plc said an experimental drug improved wakefulness and reduced daytime sleepiness in people with a form of narcolepsy, a finding that suggests a promising new class of medicines could help more patients than originally expected.

Questions still remain about safety and effectiveness.

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food and Drug Administration, a positive development for what has been a contentious product at the agency.

The FDA wants to withdraw approval of Amgen’s drug after years on the market. The company is defending it.

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk.

Biogen Inc. shares declined after additional data from a mid-stage study of its Alzheimer’s drug diranersen failed to show convincing evidence of benefit, as a deeper dive into the results found hints of improvement in some areas.

Johnson & Johnson reported second-quarter sales above expectations on strong growth of drugs for cancer, inflammatory diseases and treatment-resistant depression.